Anti-Infective Drugs Advisory Committee; Notice of Meeting, 63407-63408 [2014-25218]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 205 / Thursday, October 23, 2014 / Notices
receipt of your response, but will not
receive individualized feedback on any
suggestions.
Postal Mail: ACF/Office of Child
Support Enforcement, Attn: OCSE
Report—Sheila Drake, 370 L’Enfant
Promenade SW., 4th Floor East,
Washington, DC 20447. Submissions by
postal mail must be received by the
deadline, and should allow sufficient
time for security processing.
SUPPLEMENTARY INFORMATION: This
Request for Information offers the
opportunity for interested individuals
and organizations to provide input on
specific Report requirements or other
information that would be valuable to
the Report development.
mstockstill on DSK4VPTVN1PROD with NOTICES
Background
H.R. 4980 (Pub. L. 113–183),
Preventing Sex Trafficking and
Strengthening Families Act (Act) of
2014 was passed by both the House and
Senate and then signed by the President
on September 29, 2014. Under the Act’s
Title III—Improving International Child
Support Recovery, Section 305—Report
to Congress, the Secretary, in
conjunction with the strategic plan, is
directed to review and provide
recommendations for cost-effective
improvements to the child support
enforcement program funded under title
IV–D of the Social Security Act and
ensure that the plan addresses the
effectiveness and performance of the
program, analyzes program practices,
identifies possible new collection tools
and approaches, and identifies strategies
for holding parents accountable for
supporting their children and for
building the capacity of parents to pay
child support, with specific attention
given to matters including front-end
services, ongoing case management,
collections, tribal-state partnerships,
interstate and intergovernmental
interactions, program performance, data
analytics, and information technology.
This shall be done in consultation with
stakeholders including state, tribal, and
county child support directors; judges
who preside over family courts and
organizations that represent the judges;
custodial and noncustodial parents and
the organizations that represent them;
and fiduciaries such as financial
institutions and employers. The
Secretary shall submit a report to
Congress not later than June 30, 2015,
which will include:
• An analysis of the effectiveness of
state child support programs;
• Recommendations for methods to
enhance the effectiveness of child
support programs and collection
practices;
VerDate Sep<11>2014
16:52 Oct 22, 2014
Jkt 235001
• A review of state best practices in
regards to establishing and operating
state and multistate lien registries;
• A compilation of state recovery and
distribution policies;
• Options, with analysis, for methods
to engage noncustodial parents in the
lives of their children through
consideration of parental time and
visitation with children;
• An analysis of the role of alternative
dispute resolution in making child
support determinations;
• Identification of best practices for
determining which services and support
programs available to custodial and
noncustodial parents are nonduplicative, evidence-based, produce
quality outcomes, and connect parents
to those services and support programs.
Identification of best practices for
providing employment support, job
training, and job placement for custodial
and noncustodial parents. Identification
of best practices for establishing services
and supports and child support tracking
with options for preventing and
resolving uncollectible arrears;
• Options, with analysis, for methods
for states to use to collect child support
payments from individuals who owe
excessive arrearages;
• A review of state practices used to
determine which individuals are
excluded from the requirement to be
reported to the Passport Denial program,
including the extent to which
individuals are able to successfully
contest or appeal decisions; and
• Options, with analysis, for such
legislative and administrative actions as
are determined to be appropriate for
improvement in child support
enforcement.
Additional Instructions Regarding
Comments To Be Submitted
In your comments, please reference
the specific paragraph of the legislation
or issue area. Please do not include in
your comments information of a
confidential nature, such as sensitive
personal information or proprietary
information. Information obtained as a
result of this notice may be used by the
Federal Government for Report
development. Please be aware that your
comments may be posted online or cited
in the Report.
Authority: Sec. 305, Pub. L. 113–183, 128
Stat. 1919.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2014–25024 Filed 10–22–14; 8:45 am]
BILLING CODE 4184–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
63407
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
Anti-Infective Drugs Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Anti-Infective
Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 4, 2014, from 8:30
a.m. to 5 p.m.
Location: The Marriott Inn and
Conference Center, University of
Maryland University College (UMUC),
The Ballroom, 3501 University Blvd.
East, Hyattsville, MD 20783. The
conference center’s telephone number is
301–985–7300.
Contact Person: Jennifer Shepherd,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email: AIDAC@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
issues related to clinical development
programs and clinical trial designs for
antibacterial products for the treatment
of patients with serious bacterial
infections for which there are limited or
no therapeutic options.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
E:\FR\FM\23OCN1.SGM
23OCN1
mstockstill on DSK4VPTVN1PROD with NOTICES
63408
Federal Register / Vol. 79, No. 205 / Thursday, October 23, 2014 / Notices
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 19, 2014.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
November 10, 2014. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by November 12, 2014.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Jennifer
Shepherd at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
VerDate Sep<11>2014
16:52 Oct 22, 2014
Jkt 235001
Dated: October 17, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–25218 Filed 10–22–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
estimate, below, or any other aspect of
the ICR.
DATES: Comments on this Information
Collection Request must be received no
later than December 22, 2014.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 10–29, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
Partnerships for Care (P4C).
Supplemental Funding Progress Reports
OMB No.: 0915–xxxx—New.
Abstract: Partnerships for Care (P4C):
Health Departments and Health Centers
Collaborating to Improve HIV Health
Outcomes is a 3-year cross-HHS project
funded through the Secretary’s Minority
AIDS Initiative (MAI) Fund and the
Affordable Care Act (ACA). The goals of
the P4C project are to build sustainable
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
partnerships among CDC-funded state
health departments (including
Massachusetts, New York, Maryland,
and Florida) and HRSA-funded health
centers to support expanded HIV service
delivery in communities highly
impacted by HIV, especially among
racial/ethnic minorities. State health
departments and health centers will
work together to increase the
identification of undiagnosed HIV
infection, establish new access points
for HIV care and treatment, and improve
HIV outcomes along the continuum of
care for people living with HIV (PLWH)
(see P4C fact sheet at https://
www.cdc.gov/hiv/prevention/
demonstration/p4c/ and HHS
press release at https://www.hhs.gov/
news/press/2014pres/07/
20140715a.html). Each eligible health
center (22 across four funded states) will
receive up to $500,000 annually in
HRSA supplemental funding (totaling
$33M across the 3-year project period)
to integrate high-quality, comprehensive
HIV services into their primary care
programs; and to work in collaboration
with their state health department to (1)
identify people with undiagnosed HIV
infection, (2) link newly diagnosed
individuals to care, and (3) retain
patients living with HIV in care. Health
centers must implement activities in
five focus areas including workforce
development, infrastructure
development, HIV service delivery,
partnership development, and quality
improvement and evaluation. Health
centers must demonstrate progress
toward implementing all required P4C
activities and improving health care
outcomes across the HIV care
continuum (see https://aids.gov/federalresources/policies/care-continuum/).
Need and Proposed Use of the
Information: HRSA/Bureau of Primary
Health Care (BPHC) proposes
standardized data collection and
reporting by the 22 health centers
participating in the P4C project to
achieve the following purposes:
1. Ensure appropriate stewardship of
federal funds.
2. Support HHS efforts to streamline
HIV data collection and reporting.
3. Assess health center progress in
implementing approved work plans and
meeting other P4C goals and objectives.
4. Assess health center progress in
improving HIV outcomes across the HIV
care continuum.
5. Support health center use of patient
data to improve quality of HIV care.
6. Identify training and technical
assistance needs among participating
health centers.
7. Support identification and
dissemination of effective models and
E:\FR\FM\23OCN1.SGM
23OCN1
]]>Agencies
[Federal Register Volume 79, Number 205 (Thursday, October 23, 2014)]
[Notices]
[Pages 63407-63408]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25218]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0001]
Anti-Infective Drugs Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Anti-Infective Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 4, 2014, from
8:30 a.m. to 5 p.m.
Location: The Marriott Inn and Conference Center, University of
Maryland University College (UMUC), The Ballroom, 3501 University Blvd.
East, Hyattsville, MD 20783. The conference center's telephone number
is 301-985-7300.
Contact Person: Jennifer Shepherd, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-
8533, email: AIDAC@fda.hhs.gov, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A
notice in the Federal Register about last minute modifications that
impact a previously announced advisory committee meeting cannot always
be published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
Agenda: The committee will discuss issues related to clinical
development programs and clinical trial designs for antibacterial
products for the treatment of patients with serious bacterial
infections for which there are limited or no therapeutic options.
FDA intends to make background material available to the public no
later than 2 business days before the meeting.
[[Page 63408]]
If FDA is unable to post the background material on its Web site prior
to the meeting, the background material will be made publicly available
at the location of the advisory committee meeting, and the background
material will be posted on FDA's Web site after the meeting. Background
material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee
meeting link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
November 19, 2014. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before November 10, 2014. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by November 12, 2014.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Jennifer Shepherd at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 17, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-25218 Filed 10-22-14; 8:45 am]
BILLING CODE 4164-01-P
